WHO vaccine-preventable diseases: monitoring system. 2015 global summary

Last updated 15-Jul-2015 (Data received as of 10-Jul-2015)
Next overall update Fall 2015
EPI mother and child logo         
Select a country

Development status: Developing GNI / capita (US$): 10'8501 Infant (under 12 months) mortality rate: 122
GDP / capita (US$): 19'2501 Child (under 5 years) mortality rate: 142

Population data in thousands3

  2014  2013  2012  2011  2010  2000  1990  1980 
Total population 75'837  74'933  73'997  73'059  72'138  63'174  53'995  43'906 
Births 1'252  1'261  1'268  1'275  1'282  1'356  1'407  1'551 
Surviving infants 1'239  1'246  1'253  1'259  1'264  1'315  1'316  1'385 
Pop. less than 5 years 6'339  6'355  6'362  6'363  6'359  6'571  6'648  6'641 
Pop. less than 15 years 19'185  19'224  19'249  19'261  19'262  19'364  19'575  17'588 
Female 15-49 years 20'486  20'288  20'075  19'859  19'647  17'275  13'675  10'403 

Number of reported case

(Click for retrospective incidence data for Turkey)
Diphtheria 20  86 
Japanese encephalitis
Measles 565  7'405  349  111  16'244  11'372  8'618 
Mumps 457  597  834  1'609  1'525 
Pertussis 68  33  18  242  48  510  454  1'520 
Polio* 24  182 
Rubella 31  81  43  1'734  64 
Rubella (CRS)
Tetanus (neonatal) 26  67 
Tetanus (total)** 13  15  11  24  25  38  123  48 
Yellow fever
* Polio refers to all polio cases (indigenous or imported), including polio cases caused by vaccine derived polio viruses (VDPV). For desagregated data please click on this hyperlink: https://extranet.who.int/polis/public/CaseCount.aspx
it does not include cases of vaccine-associated paralytic polio (VAPP) and cases of non polio acute flaccid paralysis [AFP]).
** Neonatal Tetanus and Total Tetanus cases equality may be the result from a lack of non-Neonatal Tetanus surveillance system.

Percentage target population vaccinated by antigen

Hovering over an antigen reveals its fuller definition
  Most recent coverage survey4  

Official country estimates5

  (Click for retrospective coverage estimates data for Turkey)
Vaccine year result method % card seen                                                
BCG 2007  96  DHS   73  95  96  96  96  97  82  16  74 
DTP1 2007  97  DHS   73  97  97  97  98  98  92 
DTP3 2007  89  DHS   73  96  98  97  97  97  85  74  42 
DTP4          97 
IPV1          97 
HepB_BD          99  97  97 
HepB3 2007  86  DHS   73  96  97  97  96  96  71 
Hib3          96  98  97  97  97 
JapEnc         
MCV1          94  98  96  98  97  86  67  27 
MCV2          88  98  85  86  91 
PCV1          96  97  97  98 
PCV3          96  97  97  96  93 
Pol3 2007  89  DHS   73  96  98  97  97  97  85  74  63 
Rota1         
Rota_last         
Rubella1          94  98  96  98  97 
TT2plus 1997  29  DHS   39  59  61  62  57  51  36  18 
PAB         
VAD1         
YFV         
  ° indicates that more than 1 survey occurred that year

  Next update: Mid July 2016

WHO-UNICEF estimates6

  (Click for full retrospective WHO-UNICEF coverage estimates data for Turkey)
BCG 95  96  96  96  97  96  93 
DTP1 97  99  97  98  98  92  94  67 
DTP3 96  98  97  97  97  85  84  42 
HepB3 96  97  97  96  96  71 
HepB_BD 99  99  97  97  97 
Hib3 96  98  97  97  97 
MCV1 94  98  96  98  97  87  78  27 
MCV2 88  98  85  86  91 
PAB 90  90  90  90  90  50  20 
PCV3 96  97  97  96  93 
Pol3 96  98  97  97  97  85  84  63 
Rota_last

Number of districts in the country 81  Proportion of
districts reporting
DTP3 coverage:
% of coverage reports received at national
level vs number of reports expected
100 
   
/
|
|
\
Greater or equal to 90% 99
From 80 to 89% 1
From 50 to 79% 0
Less than 50% 0
Proportion of districts
not reporting DTP3 coverage
0
 

Immunization Schedule (2014 or latest available)

Hovering over an antigen reveals its fuller definition
Vaccine Schedule Entire country Comment
BCG 2 months; Yes
DT Yes risk group
DTaPHibIPV 2, 4, 6, 18 months; Yes
DTaPIPV 6 years; Yes
HepA 18, 24 months; Yes
HepB_Pediatric birth; 1, 6 months; Yes
MMR 12 months; 6 years; Yes
OPV 6, 18 months; Yes
Pneumo_conj 2, 4, 6, 12 months; Yes
Td 1st contact; +1, +6 months; +1, +1 years; Yes
Varicella 12 months; Yes

Immunizaton indicators

Indicator Expected answer 2014  2013  2012  2011  2010  2009  2008 

Planning and management

Has the country a Multi-Year Plan (MYP) for immunization? Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes  Yes 
What years does the MYP cover? number 2014-2017  2014-2018  2013-2017  5 years  2010-2014  2009-2013  2008-2013 
Nº of districts with microplans that include activities to raise immunization coverage number NA  81         

System performance

Total Nº districts in country number 81  81  81  81  81  81  81 
Nº districts with DTP3 coverage >=80% number 81  81  81  81  81  81  81 
% of districts with DTP3 coverage >=80% From 0 to 100% 100  100  100  100  100  100  100 
Nº districts with measles (MCV1) coverage >=95% number 44  75  52  73  70  65  50 
% of districts with MCV1 coverage >=95% From 0 to 100% 54  93  64  90  86  80  62 

Safety

Has the country a vaccine adverse events review committee? Yes/No/NR/ND Yes  Yes  Yes  Yes  Yes     
Is there a national system to monitor adverse events following immunization (AEFI)? Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes  Yes 

Finance

Immunization expenditure financed, using Government funds? From 0 to 100% 100  100  100  100  100  100 

National Immunization Advisory Mechanism

Has the country a standing technical advisory group on immunization (NITAG)? Yes/No/NR Yes  Yes  Yes  Yes  Yes     

Sources

 1  "The 2015 World Bank Development Indicators Online", GDP per capita is PPP adjusted.
 2  World Health Statistics 2013, data for 2012
 3  "United Nations, Population Division. The World Population Prospects - the 2012 revision". New York, 2013.
 4  UNICEF/WHO survey database
 5  If no official estimate is available, the administrative coverage is reported. '*' indicates coverage over 99.5%.
 6  WHO-UNICEF estimates.